Novel genes associated with malignant melanoma but not benign melanocytic lesions

被引：426

作者：

Talantov, D ^{[1
]}

Mazumder, A ^{[1
]}

Yu, JX ^{[1
]}

Briggs, T ^{[1
]}

Jiang, YQ ^{[1
]}

Backus, J ^{[1
]}

Atkins, D ^{[1
]}

Wang, YX ^{[1
]}

机构：

[1] Johnson & Johnson Co, Veridex LLC, San Diego, CA 92121 USA

来源：

CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 20期

关键词：

D O I：

10.1158/1078-0432.CCR-05-0683

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: Cutaneous melanoma is a common, aggressive cancer with increasing incidence. The identification of melanoma-specific deregulated genes could provide molecular markers for lymph node staging assays and further insight into melanoma tumorigenesis. Experimental Design:Total RNA isolated from 45 primary melanoma, 18 benign skin nevi, and 7 normal skin tissue specimens were analyzed on an Affymetrix Hu133A microarray containing 22,000 probe sets. Results: Hierarchical clustering revealed a distinct separation of the melanoma samples from the benign and normal specimens. Novel genes associated with malignant melanoma were identified. Differential gene expression of two melanoma-specific genes, PLAB and VCAM, were tested by a one-step quantitative reverse transcription-PCR assay on primary malignant melanoma, benign nevi, and normal skin samples, as well as on malignant melanoma lymph node metastasis and melanoma-free lymph nodes. The performance of the markers was compared with conventional melanoma markers such as tyrosinase, gp100, and MART1. Conclusion: Our study systematically identified novel melanoma-specific genes and showed the feasibility of using a combination of PLAB and L1CAM in a reverse transcription-PCR assay to differentiate clinically relevant samples containing benign or malignant melanocytes.

引用

页码：7234 / 7242

页数：9